NetScientific PLC - London-based deep tech and life sciences venture capital investor - Says its portfolio company, PDS Biotechnology Corp’s Versamune meets endpoints in a phase three trial for patients with HPV. NetScientific holds a 3.5% shareholding in PDS. Versamune is a T cell-activating platform that effectively stimulates a precise immune system response to a cancer-specific protein.

Current stock price: 62.39 pence, down 0.2%

12-month change: down 16%

Copyright 2024 Alliance News Ltd. All Rights Reserved.